Brief: Altimmune Receives FDA Breakthrough Therapy Designation For Pemvidutide In Mash
05/01/2026 14:14
Jan 5 (Reuters) - Altimmune Inc ALT.O: ALTIMMUNE RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR PEMVIDUTIDE IN MASH Source text: ID:nGNX7FXWgz Further company coverage: ALT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Altimmune
See all newsFactbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Boehringer-Zealand's obesity drug shows promise in cutting visceral, liver fat
U.S. RESEARCH ROUNDUP-Costco Wholesale, HCA Healthcare, Micron Technology
Boehringer-Zealand drug leads to 16.6% weight loss in late-stage trial (updated)